Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Myriad Genetics (NASDAQ: MYGN) announced the publication of a real-world study in JCO Precision Oncology demonstrating the effectiveness of their RiskScore® breast cancer risk assessment tool. The study showed that RiskScore predicted different risk levels than the Tyrer-Cuzick model for nearly 20% of patients. Notably, patients with ≥20% lifetime breast cancer risk identified by RiskScore were more likely to receive guidelines-aligned screening, including mammography, breast MRI, and genetic counseling.
RiskScore, which is integrated into Myriad's MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model to predict five-year and remaining lifetime breast cancer risk. The study findings suggest that clinicians are effectively utilizing RiskScore results to make informed decisions about patient risk management and screening recommendations.
Myriad Genetics (NASDAQ: MYGN) ha annunciato la pubblicazione di uno studio real-world su JCO Precision Oncology che dimostra l'efficacia del loro strumento di valutazione del rischio per il cancro al seno RiskScore®. Lo studio ha evidenziato che RiskScore ha previsto livelli di rischio differenti rispetto al modello Tyrer-Cuzick per quasi il 20% dei pazienti. In particolare, i pazienti con un rischio di cancro al seno a vita ≥20% identificati da RiskScore avevano maggiori probabilità di ricevere screening conformi alle linee guida, inclusi mammografia, risonanza magnetica al seno e consulenza genetica.
RiskScore, integrato nel test per il cancro ereditario MyRisk® di Myriad, combina un punteggio di rischio poligenico (PRS) validato per tutte le ascendenze con il modello Tyrer-Cuzick per prevedere il rischio di cancro al seno a cinque anni e per il resto della vita. I risultati dello studio suggeriscono che i clinici stanno utilizzando efficacemente i risultati di RiskScore per prendere decisioni informate sulla gestione del rischio dei pazienti e sulle raccomandazioni di screening.
Myriad Genetics (NASDAQ: MYGN) anunció la publicación de un estudio en el mundo real en JCO Precision Oncology que demuestra la efectividad de su herramienta de evaluación de riesgo de cáncer de mama RiskScore®. El estudio mostró que RiskScore predijo niveles de riesgo diferentes a los del modelo Tyrer-Cuzick en casi el 20% de los pacientes. Notablemente, los pacientes con un riesgo de cáncer de mama de por vida ≥20% identificado por RiskScore tenían más probabilidades de recibir exámenes de detección alineados con las guías, incluyendo mamografía, resonancia magnética mamaria y asesoramiento genético.
RiskScore, que está integrado en la prueba de cáncer hereditario MyRisk® de Myriad, combina una puntuación de riesgo poligénico (PRS) validada para todas las ascendencias con el modelo Tyrer-Cuzick para predecir el riesgo de cáncer de mama a cinco años y el riesgo de por vida restante. Los hallazgos del estudio sugieren que los clínicos están utilizando eficazmente los resultados de RiskScore para tomar decisiones informadas sobre la gestión del riesgo del paciente y las recomendaciones de detección.
Myriad Genetics(NASDAQ: MYGN)는 JCO Precision Oncology에 실제 임상 데이터를 기반으로 한 연구 결과를 발표하며 자사의 유방암 위험 평가 도구 RiskScore®의 효과를 입증했습니다. 연구에 따르면 RiskScore는 Tyrer-Cuzick 모델과 비교해 약 20%의 환자에서 다른 위험 수준을 예측했습니다. 특히 RiskScore로 평생 유방암 위험이 20% 이상으로 평가된 환자들은 유방촬영술, 유방 MRI, 유전 상담 등 가이드라인에 따른 검진을 받을 가능성이 더 높았습니다.
RiskScore는 Myriad의 MyRisk® 유전성 암 검사에 통합되어 있으며, 모든 인종에 대해 검증된 다유전자 위험 점수(PRS)와 Tyrer-Cuzick 모델을 결합해 5년 및 남은 평생 유방암 위험을 예측합니다. 연구 결과는 임상의들이 RiskScore 결과를 효과적으로 활용해 환자의 위험 관리 및 검진 권고에 대한 정보를 바탕으로 의사 결정을 내리고 있음을 시사합니다.
Myriad Genetics (NASDAQ : MYGN) a annoncé la publication d'une étude en conditions réelles dans JCO Precision Oncology démontrant l'efficacité de leur outil d'évaluation du risque de cancer du sein RiskScore®. L'étude a montré que RiskScore prédisait des niveaux de risque différents de ceux du modèle Tyrer-Cuzick pour près de 20 % des patientes. Notamment, les patientes avec un risque à vie de cancer du sein ≥20 % identifié par RiskScore étaient plus susceptibles de bénéficier d’un dépistage conforme aux recommandations, incluant la mammographie, l’IRM mammaire et le conseil génétique.
RiskScore, intégré au test MyRisk® Hereditary Cancer de Myriad, combine un score de risque polygénique (PRS) validé pour toutes les ascendances avec le modèle Tyrer-Cuzick pour prédire le risque de cancer du sein à cinq ans et sur le reste de la vie. Les résultats de l’étude suggèrent que les cliniciens utilisent efficacement les résultats de RiskScore pour prendre des décisions éclairées concernant la gestion du risque des patientes et les recommandations de dépistage.
Myriad Genetics (NASDAQ: MYGN) gab die Veröffentlichung einer Real-World-Studie in JCO Precision Oncology bekannt, die die Wirksamkeit ihres Brustkrebs-Risikobewertungstools RiskScore® belegt. Die Studie zeigte, dass RiskScore bei fast 20 % der Patienten andere Risikostufen vorhersagte als das Tyrer-Cuzick-Modell. Besonders Patienten mit einem lebenslangen Brustkrebsrisiko von ≥20 %, das durch RiskScore identifiziert wurde, erhielten mit höherer Wahrscheinlichkeit screenings gemäß den Richtlinien, einschließlich Mammographie, Brust-MRT und genetischer Beratung.
RiskScore, das in Myriads MyRisk® Hereditary Cancer Test integriert ist, kombiniert einen polygenen Risikoscore (PRS), der für alle Abstammungen validiert wurde, mit dem Tyrer-Cuzick-Modell, um das Fünfjahres- und verbleibende lebenslange Brustkrebsrisiko vorherzusagen. Die Studienergebnisse deuten darauf hin, dass Kliniker die RiskScore-Ergebnisse effektiv nutzen, um fundierte Entscheidungen zur Risikomanagement und Screening-Empfehlungen für Patienten zu treffen.
- RiskScore identified different risk levels than traditional model in 20% of patients, potentially improving risk assessment accuracy
- Study validates clinical utility of RiskScore in real-world settings
- Tool demonstrates effectiveness in guiding appropriate screening decisions
- Technology is validated for all ancestries, expanding market reach
- None.
Insights
Myriad's RiskScore study shows real clinical impact, improving breast cancer screening decisions and validating their precision medicine approach.
The publication of Myriad's RiskScore study in JCO Precision Oncology represents significant clinical validation for this breast cancer risk assessment tool. The study demonstrates meaningful differentiation from traditional risk models, with RiskScore predicting different risk levels than the standard Tyrer-Cuzick model for
What makes these results particularly valuable is the evidence of real-world clinical utility. The data clearly shows that patients identified by RiskScore as having ≥
The integration of a polygenic risk score (PRS) validated across all ancestries with the Tyrer-Cuzick model represents an important advancement in risk stratification. Many genetic assessments have historically shown limitations in diverse populations, so this inclusive validation expands the tool's clinical applicability.
For Myriad Genetics, this publication in a respected oncology journal strengthens the value proposition of their MyRisk Hereditary Cancer Test portfolio. By demonstrating that RiskScore influences medical management decisions, Myriad establishes stronger evidence for the test's clinical relevance in precision medicine.
As precision oncology continues to evolve, tools that enable more personalized risk assessment and screening recommendations represent an important advancement. This study provides concrete evidence that Myriad's polygenic approach can help clinicians tailor breast cancer screening more precisely to individual patient risk profiles.
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer.
The study, “Association of Polygenic-based Breast Cancer Risk Prediction with Patient Management”, was first shared at the 2024 ASCO® Annual Meeting. Key findings include:
- RiskScore predicted a different risk level than Tyrer-Cuzick for nearly
20% of patients - Patients with a ≥
20% lifetime risk of breast cancer predicted by RiskScore were significantly more likely to have guidelines-aligned screening, such as mammography, breast MRI, and genetic counseling compared to those with <20% lifetime risk. - RiskScore results appeared to influence the way clinicians managed patients at increased risk of breast cancer
“Polygenic-based risk predictors are relatively new, and few data have been gathered about how they are being used in clinical practice,” said Allison Kurian, MD, MSc, Professor of Medicine and of Epidemiology and Population Health at Stanford University School of Medicine and senior author on the study. “This study offered reassurance that patients undergo appropriate breast screening after RiskScore testing and suggests that clinicians are considering RiskScore results to make recommendations about risk-based screening for their patients.”
“This real-world, large-scale study represents important progress in understanding how polygenic-based risk scores influence medical management tailored to a patient’s individual risk level,” said Katie Johansen Taber, PhD, VP Clinical Product Research & Partnerships, Myriad Genetics. “With MyRisk with RiskScore, patients may gain insights into their genetically driven risk of developing breast cancer, and clinicians and patients can work together to make informed, proactive decisions on how to best manage that risk.”
About the Study
To conduct this study, patients’ RiskScore results were de-identified and linked with insurance claims data to determine what type of breast cancer screening was undertaken in the one year following genetic testing. Mammography in those under age 40, breast MRI, and genetic counseling, all recommended by guidelines for individuals at increased risk of breast cancer, were compared before and after receiving RiskScore results. The study found that patients with a
About MyRisk® Hereditary Cancer Test with RiskScore®
MyRisk Hereditary Cancer Test with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients of all ancestries with a five-year and remaining lifetime breast cancer risk assessment individualized to them.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the study represents important progress in understanding how polygenic-based risk scores influence medical management tailored to a patient’s individual risk level, that the study suggests clinicians are considering RiskScore results to make recommendations about risk-based screening for their patients, and that the company believes MyRisk with RiskScore may help patients gain insights into their genetically driven risk of developing breast cancer, supporting informed, proactive decision-making between patients and clinicians about how to best manage that risk. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
What are the key findings of Myriad Genetics' (MYGN) RiskScore study published in JCO Precision Oncology?
How does Myriad Genetics' RiskScore work for breast cancer risk assessment?
What impact does MYGN's RiskScore have on patient care?
What makes Myriad's RiskScore different from traditional risk assessment methods?
